Shi Y - Search Results

1

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.

Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Koul D, et al. Among authors: shi y. Oncogene. 2002 Apr 4;21(15):2357-64. doi: 10.1038/sj.onc.1205296. Oncogene. 2002. PMID: 11948419

2

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. Fueyo J, et al. Among authors: shi yx. Oncogene. 2000 Jan 6;19(1):2-12. doi: 10.1038/sj.onc.1203251. Oncogene. 2000. PMID: 10644974

3

VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells.

Ke LD, Shi YX, Yung WK. Ke LD, et al. Cancer Res. 2002 Mar 15;62(6):1854-61. Cancer Res. 2002. PMID: 11912165

4

Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth.

Tang P, Jasser SA, Sung JC, Shi Y, Steck PA, Yung WK. Tang P, et al. Among authors: shi y. J Neurooncol. 1999 Jun;43(2):127-35. doi: 10.1023/a:1006272019933. J Neurooncol. 1999. PMID: 10533724

5

The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines.

Ke LD, Shi YX, Im SA, Chen X, Yung WK. Ke LD, et al. Among authors: shi yx. Clin Cancer Res. 2000 Jun;6(6):2562-72. Clin Cancer Res. 2000. PMID: 10873113

6

A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes.

Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK. Ke LD, et al. Among authors: shi yx. Int J Oncol. 1998 Jun;12(6):1391-6. doi: 10.3892/ijo.12.6.1391. Int J Oncol. 1998. PMID: 9592205

7

PAX6 suppresses growth of human glioblastoma cells.

Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. Zhou YH, et al. J Neurooncol. 2005 Feb;71(3):223-9. doi: 10.1007/s11060-004-1720-4. J Neurooncol. 2005. PMID: 15735909

8

Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.

Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Konopleva M, et al. Mol Cancer Ther. 2006 Feb;5(2):317-28. doi: 10.1158/1535-7163.MCT-05-0350. Mol Cancer Ther. 2006. PMID: 16505105

9

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Zhang W, et al. J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29. J Natl Cancer Inst. 2008. PMID: 18230792 Clinical Trial.

10

The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo.

Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N Jr, Konopleva M, Andreeff M. Ling X, et al. Among authors: shi y. PLoS One. 2013;8(3):e58426. doi: 10.1371/journal.pone.0058426. Epub 2013 Mar 6. PLoS One. 2013. PMID: 23484027 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31,866 results

Search Page